Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydrocodone + acetaminophen + promethazine
- Development stage
- Phase 3
- Lead developer
- Charleston Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This immediate-release combination drug contains **hydrocodone** (a semi-synthetic opioid agonist for pain relief), **acetaminophen** (a non-opioid analgesic and antipyretic), and **promethazine** (a first-generation antihistamine with antiemetic, sedative, and anti-allergic properties). Hydrocodone acts as a mu-opioid receptor agonist to reduce pain perception, acetaminophen provides analgesia and fever reduction via central mechanisms, and promethazine, an H1 histamine receptor antagonist, reduces nausea (notably opioid-induced nausea/vomiting), provides additional mild sedation, and may reduce allergic responses. This combination (marketed as Hydexor) was developed specifically for the **short-term management of acute pain** that requires an opioid, particularly in patients prone to opioid-induced nausea and vomiting, with the goal of addressing both pain and opioid-related side effects[2].
- Brand names
- Hydexor
- Other names
- hydrocodone acetaminophen promethazine
02
Targets
COXDOR (Opioid Receptor Delta 1)HRH1 (Histamine H1 Receptor)ALB (Human serum albumin)MOR (Mu opioid receptor)ADRA1 (Alpha-1 adrenergic receptor family)DRD2 (Dopamine D2 Receptor)M1 (Muscarinic acetylcholine receptor M1)
Beyond the preview
Go deeper on hydrocodone + acetaminophen + promethazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydrocodone + acetaminophen + promethazine.